---
title: "Klotho Neurosciences - W27 | 10-Q: FY2025 Q2 EPS: USD -0.12"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/253437697.md"
datetime: "2025-08-18T10:13:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/253437697.md)
  - [en](https://longbridge.com/en/news/253437697.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/253437697.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/253437697.md) | [繁體中文](https://longbridge.com/zh-HK/news/253437697.md)


# Klotho Neurosciences - W27 | 10-Q: FY2025 Q2 EPS: USD -0.12

EPS: As of FY2025 Q2, the actual value is USD -0.12.

EBIT: As of FY2025 Q2, the actual value is USD -4.093 M.

### Segment Revenue

-   The company did not generate any revenue for the three and six months ended June 30, 2025, and 2024.

### Operational Metrics

-   **Net Loss**: For the three months ended June 30, 2025, the net loss was $4,093,231, compared to $451,639 for the same period in 2024. For the six months ended June 30, 2025, the net loss was $6,327,213, compared to $1,123,683 for the same period in 2024.
-   **Operating Expenses**: Operating expenses for the three months ended June 30, 2025, were $1,892,852, compared to $395,607 for the same period in 2024. For the six months ended June 30, 2025, operating expenses were $3,479,820, compared to $817,652 for the same period in 2024.

### Cash Flow

-   **Net Cash Used in Operating Activities**: For the six months ended June 30, 2025, net cash used in operating activities was $3,522,178, compared to $929,399 for the same period in 2024.
-   **Net Cash Provided by Financing Activities**: For the six months ended June 30, 2025, net cash provided by financing activities was $11,889,383, compared to $1,895,424 for the same period in 2024.

### Unique Metrics

-   **Share-based Compensation**: The company recorded share-based compensation of $390,195 for the three months ended June 30, 2025, and $885,695 for the six months ended June 30, 2025.

### Future Outlook and Strategy

-   **Core Business Focus**: The company is focused on developing essential medicines for chronic diseases, including cancer, cardiovascular, and neurodegenerative disorders, using its licensed platforms and proprietary technologies.
-   **Non-Core Business**: The company terminated the Share Exchange Agreement to acquire SB Security Holdings, LLC, indicating a focus on its core business areas.
-   **Priority**: The company is dependent on obtaining additional working capital funding from the sale of equity and/or debt securities to continue its development plans and operations.

### Related Stocks

- [Klotho Neurosciences - W27 (KLTOW.US)](https://longbridge.com/en/quote/KLTOW.US.md)
- [GREENLAND MINES LTD C/WTS 21/06/2029 (TO PUR COM) (GRMLW.US)](https://longbridge.com/en/quote/GRMLW.US.md)